NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
531 Skövde |
Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
Benign sample | 37 | 0.7% | 8 | 0.2% | 7 | 0.1% | . | . | . | . | 1 | 0.0% | 4886 | 98.9% | 4939 | 100.0% |
ASCUS | 115 | 29.3% | 102 | 26.0% | 79 | 20.2% | 3 | 0.8% | 1 | 0.3% | 2 | 0.5% | 90 | 23.0% | 392 | 100.0% |
LSIL | 37 | 29.4% | 50 | 39.7% | 25 | 19.8% | . | . | . | . | . | . | 14 | 11.1% | 126 | 100.0% |
Atypical glandular cells/AGC | 2 | 13.3% | 3 | 20.0% | 5 | 33.3% | 3 | 20.0% | 1 | 6.7% | . | . | 1 | 6.7% | 15 | 100.0% |
ASC-H | 3 | 7.3% | 6 | 14.6% | 25 | 61.0% | 3 | 7.3% | 3 | 7.3% | . | . | 1 | 2.4% | 41 | 100.0% |
HSIL | . | . | 1 | 5.9% | 12 | 70.6% | . | . | 3 | 17.6% | 1 | 5.9% | . | . | 17 | 100.0% |
Suspected Adenocarcinom | . | . | . | . | . | . | . | . | 1 | 100.0% | . | . | . | . | 1 | 100.0% |
Totalt | 194 | 3.5% | 170 | 3.1% | 153 | 2.8% | 9 | 0.2% | 9 | 0.2% | 4 | 0.1% | 4992 | 90.3% | 5531 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M80703, M81403 |